Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis

CONCLUSION: Switching biologics was most commonly due to secondary lack of efficacy for skin disease. Lower ages and the presence of PsA were associated with a higher need for switching in long-term. Ustekinumab and secukinumab are superior to adalimumab in clinical practice in terms of drug survival of second-line biologics.PMID:34519227 | DOI:10.1080/17512433.2021.1979394

Source: Expert Review of Clinical Pharmacology - September 14, 2021 Category: Drugs & Pharmacology Authors: Neslihan Akdogan Sibel Dogan Ecem Bostan Duygu Gulseren Basak Yalici-Armagan Gonca Elcin Sibel Evans Aysen Karaduman Nilgun Atakan Source Type: research